R-targeted therapy PMB-CT01 for treating B-cell malignancies, including heavily pretreated follicular lymphoma.

The firms are developing the autologous CAR T-cell therapy IB-T101 as a treatment for clear cell renal cell carcinoma.

The company separately said it has started treating patients within a Phase III trial testing an ASO drug for Angelman syndrome.

The program, aimed at reducing how much Americans spend on prescription drugs, includes several precision medicines.